HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ansell, B. Search for Related Content PubMed PubMed Citation Articles by Ansell, B.

Much has been learned about preventing and treating coronary heart disease (CHD) since publication of the National Cholesterol Education Program (NCEP) Adult Treatment Panel II (ATP II) guidelines in 1993. Even with the recent release of the ATP III guidelines, clinical decision making has become increasingly complex as a result of the tremendous volume of new data, and because many common patient types do not fit precisely into the defined risk categories. The case studies presented here illustrate how data from recent trials and the clinician's judgment should be weighed together in the decision to initiate cholesterol-lowering therapy in patients with borderline risk levels, as part of a strategy for primary and secondary prevention of CHD.